Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

e global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales. For more information please visit www.us.boehringer-ingelheim.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568105PR

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient exp
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
(Date:7/23/2014)... Ill. , July 23, 2014 ... IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY ... THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ... 2014 financial results on Friday, July 25, 2014, before the ... of the earnings conference call at 8 a.m. Central time ...
(Date:7/23/2014)... 2014  RT Oncology Services Corporation today announced that ... board of directors. Mr. Mundie is currently senior advisor ... on strategic projects within the company and on technology ... and strategy officer. Mike Martin ... "Craig is a visionary technology executive. His appointment is ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3
... In Children,s DNA, a Hint of a Mutation,s Ancestral ... researchers,seeking to replicate another group,s discovery of an important ... a particular,variant in DNA that may be more helpful ... populations worldwide. The finding suggests that,the gene variant, identified ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced ... clinical study of ANX-510, CoFactor(R), for the treatment ... at the 2008,American Society of Clinical Oncology (ASCO) ... 3, 2008 in Chicago, IL., The poster ...
Cached Medicine Technology:Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 2ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 3
(Date:7/23/2014)... China,s Northwest Agricultural and Forestry University in Shaanxi province, ... memorandum of agreement that lays the groundwork for establishing ... China. , The signing ceremony was held in the ... officials of the U.S. Department of Agriculture and China,s ... a landmark event for UC Davis and for our ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Unlocking the secrets to better treating the pernicious disorders ... to a paper from American University,s Center for Behavioral ... treating obesity with therapies aimed at areas of the ... focus on the hippocampus could play a role in ... diseases, therapies and preventive measures often fall short. This ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, ... an additional side benefit -- it may improve urinary ... The study found that nearly half of women ... to the procedure. After surgery, most of those women ... study researcher Dr. Leslee Subak, professor of obstetrics, gynecology ...
(Date:7/23/2014)... catalog the molecular causes of stomach cancer, scientists, ... four subtypes of tumors based on shared mutations ... classification promises to advance clinical research to develop ... , In a report in Nature , ... said they analyzed 295 samples of gastric (stomach) ...
Breaking Medicine News(10 mins):Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... in low sunlight areas are more likely to experience ... same environment. Researchers believe that these findings should change ... study shows that across the board vitamin D recommendations ... M.D., M.B.A., clinical instructor in the department of urology ...
... well-known risk factor for heart disease. Researchers at the ... participated in an international study of 200,000 Europeans which ... pressure. The discovery, presented in Nature, is an important ... people worldwide suffer from high blood pressure and are ...
... in areas with low sunlight are up to 3 ... men and should take high levels of Vitamin D supplements, ... of Medicine. "This study shows that the current ... Vitamin D don,t work," said Adam Murphy, M.D., a clinical ...
... Tenn. September 19, 2011) The largest study ever of ... tumors carried extra copies of specific genes linked to cancer ... Hospital investigators. The findings identify possible new targets ... diffuse intrinsic pontine glioma (DIPG). Current survival rates for children ...
... , MONDAY, Sept. 19 (HealthDay News) -- Obese 8- ... than their normal-weight peers, a new study finds. In ... of height and weight, at ages 4 and 5 and ... out questionnaires that assessed children,s mental health and health-related quality ...
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... treating varicose veins, it appears that recurrence of one ... laser treatment, German researchers report. Varicose veins are ... legs. As many as 35 percent of adults suffer ...
Cached Medicine News:Health News:African-American men living in poor sunlight areas at risk for vitamin D deficiency 2Health News:Genetic factors behind high blood pressure 2Health News:One size doesn't fit all for vitamin D and men 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3Health News:Two Varicose Veins Treatments Equally Effective 2Health News:Two Varicose Veins Treatments Equally Effective 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: